Quantcast Inverness Acquires Majority Stake In Diamics
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Inverness Acquires Majority Stake In Diamics

Posted on 07/20/2007 03:24:34 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel



Diamics, a Novato, CA-based company that develops molecular-based cancer screening and diagnostic systems, has secured a $6 million equity investment from Inverness Medical Innovations (IMA). The deal gives Inverness, a leading diagnostics company specializing in women’s health, 51% of the privately held firm.

Under the terms of the agreement, Inverness will help drive commercialization of Diamics’ products. It will provide strategic and hands-on assistance with assay development, product design, and manufacturing and distribution.

Diamics is developing products to improve the effectiveness of cervical cancer screening and to make the procedure less painful. Its FDA-cleared CerCol Cervical Cancer Collection System collects cellular and fractional histological material from the entire cervix with a single, soft-tipped device. The system is used together with Diamics’ Pap-Map system, which provides a “map” of the collected sample, to help guide physicians’ subsequent decisions about colposcopy and biopsy procedures.

Diamics’ point-of-care offering, C-Map, is in pre-clinical trials. The goal with C-Map is to create a more accurate and less costly method of screening women for precancerous conditions of the uterine cervix. The system uses automation to identify abnormalities as expressed within the context of normal cellular morphology and eliminates the need for a cell by cell analysis, yielding greater sensitivity and specificity than cytology.

“We are delighted that Inverness has acknowledged the progress of the company and the value of our novel technologies focused on improving cervical cancer screening,” said Diamics CEO Peter Gombrich, in a statement.




Med Tech Sentinel is a regular contributor to BioHealth Investor
_________________
Stock Quote or
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Fri Jul 18, 2008 08:23AM
U.S. stock futures rebound on Citigroup results"S&a [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.